Posted by Michael Wonder on 11 Nov 2020
NICE publishes draft guidance on new treatment for patients with immune thrombocytopenia
11 November 2020 - The Department of Health and Social Care has asked NICE to produce guidance on using fostamatinib in the NHS in England.
Fostamatinib is not recommended, within its marketing authorisation, for treating refractory chronic immune thrombocytopenia in adults.
Clinical evidence shows that fostamatinib is moderately effective compared with placebo. There is no clinical trial evidence directly comparing fostamatinib with rituximab or mycophenolate. The company chose rituximab with ‘watch and rescue’ (monitoring until a bleed happens and treatment is needed) as its comparator. However, it did not provide any direct or indirect evidence comparing rituximab with fostamatinib.
